Abstract
S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest that this new combination is feasible and well tolerable.
Publication types
-
Clinical Trial, Phase I
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / radiotherapy*
-
Adenocarcinoma / surgery
-
Adult
-
Aged
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Combined Modality Therapy
-
Drug Combinations
-
Female
-
Humans
-
Irinotecan
-
Male
-
Maximum Tolerated Dose
-
Middle Aged
-
Neoadjuvant Therapy
-
Oxonic Acid / administration & dosage*
-
Oxonic Acid / adverse effects
-
Radiation-Sensitizing Agents / adverse effects
-
Radiation-Sensitizing Agents / therapeutic use*
-
Radiotherapy Dosage
-
Radiotherapy, High-Energy
-
Rectal Neoplasms / drug therapy*
-
Rectal Neoplasms / radiotherapy*
-
Rectal Neoplasms / surgery
-
Tegafur / administration & dosage*
-
Tegafur / adverse effects
Substances
-
Antineoplastic Agents, Phytogenic
-
Drug Combinations
-
Radiation-Sensitizing Agents
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid
-
Irinotecan
-
Camptothecin